Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- DRUG: Ibrutinib
- DRUG: Chlorambucil
Sponsor
Pharmacyclics LLC.
Collaborators